Johnson & Johnson (JNJ) Said to Settle Risperdal Case on First Day; Shares Move Higher
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $88.46 -0.15%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
EPS Growth %: +5.1%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
EPS Growth %: +5.1%
Trade JNJ Now!
Shares of Johnson & Johnson (NYSE: JNJ) are higher Monday following headlines that it settled Risperdal case on the first day of trial.
The data comes from a confidential statement announced in a Philadelphia court.
Shares are up 0.5 percent in morning trade.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The data comes from a confidential statement announced in a Philadelphia court.
Shares are up 0.5 percent in morning trade.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Strong Zale (ZLC) Results May be Positive for Signet (SIG) Into Q1 Report
- Short Sellers See the Light (HLF) (FSLR) (NFLX) (TLSA)
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
